BiotechTube

SAR245409

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
32
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Indolent Non-Hodgkin Lymphoma

Conditions

Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia

Trial Timeline

Dec 1, 2011 โ†’ May 1, 2014

NCT ID
NCT01410513

About SAR245409

SAR245409 is a phase 1 stage product being developed by Sanofi for Indolent Non-Hodgkin Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01410513. Target conditions include Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (3)

NCT IDPhaseStatus
NCT01596270Phase 1Completed
NCT01410513Phase 1Completed
NCT01403636Phase 2Completed

Competing Products

15 competing products in Indolent Non-Hodgkin Lymphoma

See all competitors
ProductCompanyStageHype Score
ME-401Kyowa KirinPhase 1
33
ME-401Kyowa KirinPhase 2
52
Linperlisib ๏ผ› RituximabJiangsu Hengrui MedicinePhase 1/2
41
GP2013NovartisPhase 1
33
Ibrutinib + GA 101RochePhase 2
52
Obinutuzumab + BendamustineRochePhase 2
52
Placebo + Rituximab + IdelalisibGilead SciencesPhase 3
76
IdelalisibGilead SciencesPhase 1/2
40
Idelalisib + Rituximab + Bendamustine + PlaceboGilead SciencesPhase 3
76
Idelalisib + Rituximab + Bendamustine + Ofatumumab + Fludarabine + Everolimus + Bortezomib + Chlorambucil + LenalidomideGilead SciencesPhase 1
32
IBI376Innovent BiologicsPhase 2
51
Copanlisib + Nivolumab + RituximabBristol Myers SquibbPhase 1
32
Copanlisib (BAY80-6946)BayerPre-clinical
20
Bendamustine at a dose of 100 mg/m2 + Bendamustine at a dose of 120 mg/m2LundbeckPhase 3
74
BezuclastinibCogent BiosciencesPre-clinical
20

Other Products from Sanofi

AdacelยฎApproved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84